Modulation of tachykinin and cytokine release in patients with coronary disease undergoing percutaneous revascularization

Clinical Immunology

Volumn 112, Issue 1, 2004, Pages 78-84

  Paroli, Marino ^a,b   Mariani, Paola ^a   Accapezzato, Daniele ^a   D'Alessandro, Mariadomenica ^a   Di Russo, Cristian ^a   Bifolco, Maura ^a   Sirinian, Maria Isabella ^a   Fedele, Francesco ^a   Bruno, Guglielmo ^a   Sardella, Gennaro ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

Coronary artery disease; Coronary stenting; Interferon ; Neurokinin A; Substance P; Tumor necrosis factor

Indexed keywords

CYTOKINE; GAMMA INTERFERON; NEUROKININ A; SUBSTANCE P; TACHYKININ; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; CYTOKINE RELEASE; DISEASE SEVERITY; FEMALE; HEART; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; IMMUNOMODULATION; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REACTION TIME; RISK FACTOR; STATISTICAL SIGNIFICANCE; TISSUE INJURY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; NEUROKININ A; SUBSTANCE P; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2942693813     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2004.03.021     Document Type: Article

References (33)

1. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn I., Detre K., Veltri L., Ricci D., Nobuyoshi M., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. 331:1994;496-501
2. Degeare V.S., Dangas G., Stone G.W., Grines C.L. Interventional procedures in acute myocardial infarction. Am. Heart J. 141:2001;15-24
3. Raff G.L., O'Neill W.W. Interventional therapy of the acute coronary syndromes. Prog. Cardiovasc. Dis. 44:2002;455-468
4. Frangogiannis N.G., Youker K.A., Rossen R.D., Gwechenberger M., Lindsey M.H., Mendoza L.H., Michael L.H., Ballantyne C.M., Smith C.W., Entman M.L. Cytokines and the microcirculation in ischemia and reperfusion. J. Mol. Cell Cardiol. 30:1998;2567-2576
5. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc. Res. 53:2002;31-47
6. Hoffmann R., Mintz G.S., Dussaillant G.R., Popma J.J., Pichard A.D., Satler L.F., Kent K.M., Griffin J., Leon M.B. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 94:1996;1247-1254
7. Paroli M., Nigri A., Pizzuto F., Benvenuto R., Gurgo A., Sardella G., Fravolini F., Berni A., Villatico-Campbell S. Local recruitment of LFA-1+lymphocytes after coronary stent implantation. Am. J. Cardiol. 87:2001;1295-1298
8. Schwartz R.S., Henry T.D. Pathophysiology of coronary artery restenosis. Rev. Cardiovasc. Med. 3:2002;S4-S9
9. Bruno G., Tega F., Bruno A., Graf U., Corelli F., Molfetta R., Barucco M. The role of substance P in cerebral ischemia. Int. J. Immunopathol. Pharmacol. 16:2003;67-72
10. Joos G.F., Germonpre P.R., Pauwels R.A. Role of tachykinins in asthma. Allergy. 55:2000;321-337
11. Severini C., Improta G., Falconieri-Erspamer G., Salvadori S., Erspamer V. The tachykinin peptide family. Pharmacol. Rev. 54:2002;285-322
12. Souza D.G., Mendonca V.A., de A.C.M.S., Poole S., Teixeira M.M. Role of tachykinin NK receptors on the local and remote injuries following ischaemia and reperfusion of the superior mesenteric artery in the rat. Br. J. Pharmacol. 135:2002;303-312
13. Campos M.M., Calixto J.B. Neurokinin mediation of edema and inflammation. Neuropeptides. 34:2000;314-322
14. Hoover D.B., Chang Y., Hancock J.C., Zhang L. Actions of tachykinins within the heart and their relevance to cardiovascular disease. Jpn. J. Pharmacol. 84:2000;367-373
15. Hoover D.B., Hossler F.E. Vasoconstrictor and dilator responses to neurokinin A in isolated guinea pig heart. Peptides. 14:1993;29-36
16. Hoover D.B., Chang Y., Hancock J.C. Characterization of responses to neurokinin A in the isolated perfused guinea pig heart. Am. J. Physiol. 275:1998;R1803-R1811
17. Chang Y., Hoover D.B., Hancock J.C., Smith F.M. Tachykinin receptor subtypes in the isolated guinea pig heart and their role in mediating responses to neurokinin A. J. Pharmacol. Exp. Ther. 294:2000;147-154
18. Mazzone A., De Servi S., Mazzucchelli I., Bossi I., Ottini E., Vezzoli M., Meloni F., Lotzinker M., Mariani G. Increased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin T. Heart. 85:2001;571-575
19. Kaplan R.C., Frishman W.H. Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. Heart Dis. 3:2001;326-332
20. Romagnani S. The Th1/Th2 paradigm. Immunol. Today. 18:1997;263-266
21. Gupta S., Pablo A.M., Jiang X., Wang N., Tall A.R., Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 99:1997;2752-2761
22. Liuzzo G., Vallejo A.N., Kopecky S.L., Frye R.L., Holmes D.R., Goronzy J.J., Weyand C.M. Molecular fingerprint of interferon-gamma signaling in unstable angina. Circulation. 103:2001;1509-1514
23. Zohlnhofer D., Richter T., Neumann F., Nuhrenberg T., Wessely R., Brandl R., Murr A., Klein C.A., Baeuerle P.A. Transcriptome analysis reveals a role of interferon-gamma in human neointima formation. Mol. Cell. 7:2001;1059-1069
24. Weyand C.M., Goronzy J.J., Liuzzo G., Kopecky S.L., Holmes D.R.Jr., Frye R.L. T-cell immunity in acute coronary syndromes. Mayo Clin. Proc. 76:2001;1011-1020
25. Farb A., Sangiorgi G., Carter A.J., Walley V.M., Edwards W.D., Schwartz R.S., Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation. 99:1999;44-52
26. Sugano M., Koyanagi M., Tsuchida K., Hata T., Makino N. In vivo gene transfer of soluble TNF-alpha receptor 1 alleviates myocardial infarction. FASEB J. 16:2002;1421-1422
27. Zhou Z., Lauer M.A., Wang K., Forudi F., Zhou X., Song X., Solowski N., Kapadia S.R., Nakada M.T., Topol E.J., Lincoff A.M. Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis. 161:2002;153-159
28. Cuesta M.C., Quintero L., Pons H., Suarez-Roca H. Substance P and calcitonin gene-related peptide increase IL-1 beta, IL-6 and TNF alpha secretion from human peripheral blood mononuclear cells. Neurochem. Int. 40:2002;301-306
29. Ho W.Z., Kaufman D., Uvaydova M., Douglas S.D. Substance P augments interleukin-10 and tumor necrosis factor-alpha release by human cord blood monocytes and macrophages. J. Neuroimmunol. 71:1996;73-80
30. Lotz M., Vaughan J.H., Carson D.A. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science. 241:1988;1218-1221
31. Marriott I., Bost K.L. Substance P receptor mediated macrophage responses. Adv. Exp. Med. Biol. 493:2001;247-254
32. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., Kuntz R.E. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349:2003;1315-1323
33. Donners M.M., Daemen M.J., Cleutjens K.B., Heeneman S. Inflammation and restenosis: implications for therapy. Ann. Med. 35:2003;523-531